BioSpace News Archive

The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.

Masimo and Temple Health announced that Temple University Hospital, a 722-bed academic medical center located in Philadelphia, is expanding its use of Masimo technologies with Centroid™, an advanced wireless patient position, orientation, activity, and respiration rate sensor, at 100 beds across its ICU units.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Richard Beckman, M.D., has joined Adverum as the company’s chief medical officer (CMO).

Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® 1.

As social isolation in the United States has been increasing among older adults, a new study shows a notable link between loneliness and dementia risk, and one that is most striking for Americans who represent a large part of the population.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference.

CooperCompanies announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer of minimally invasive medical devices focused on the fertility, obstetrics and gynecology markets.

Quantum-Si Incorporated, a life sciences tools company commercializing a single molecule protein sequencing platform, announced that it will report fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022.

Johnson & Johnson will participate in the Cowen 42nd Annual Health Care Virtual Conference on Monday, March 7th.

Bridge Biotherapeutics (KQ288330), today announced a research collaboration to discover and characterize novel reactive groups that target non-cysteine residues to uncover new druggable sites in targets of high therapeutic value.